Purpose of Review

Glioblastoma (GBM) is the most common malignant primary brain tumor, and the available treatment options are limited. This article reviews the recent preclinical and clinical investigations that seek to expand the repertoire of effective medical and radiotherapy options for GBM.

Recent Findings

Recent phase III trials evaluating checkpoint inhibition did not result in significant survival benefit. Select vaccine strategies have yielded promising results in early phase clinical studies and warrant further validation. Various targeted therapies are being explored but have yet to see breakthrough results. In addition, novel radiotherapy approaches are in development to maximize safe dose delivery.

Summary

A multitude of preclinical and clinical studies in GBM explore promising immunotherapies, targeted agents, and novel radiation modalities. Recent phase III trial failures have once more highlighted the profound tumor heterogeneity and diverse resistance mechanisms of glioblastoma. This calls for the development of biomarker-driven and personalized treatment approaches.

中文翻译：

---

胶质母细胞瘤的新型疗法。

审查目的

胶质母细胞瘤（GBM）是最常见的恶性原发性脑肿瘤，可用的治疗选择有限。本文回顾了最近的临床前和临床研究，这些研究试图扩大GBM的有效医学和放射疗法选择范围。

最近的发现

最近的评估检查点抑制作用的III期临床试验并未带来明显的生存获益。精选的疫苗策略已在早期临床研究中取得了可喜的成果，并有待进一步验证。目前正在探索各种靶向疗法，但尚未见突破性结果。另外，正在开发新颖的放射疗法方法以最大化安全剂量的递送。

概要

GBM的大量临床前和临床研究探索了有前途的免疫疗法，靶向药物和新颖的放射方式。最近的三期试验失败再次突出了胶质母细胞瘤的深层肿瘤异质性和多种耐药机制。这就要求开发生物标记驱动的个性化治疗方法。